Christian B. Fulda
Metropolregion München
1587 Follower:innen
500+ Kontakte
Info
I am a life sciences lawyer. I advise biotech, pharma and medtech companies and help them…
Aktivitäten
-
The demand for data centers driven by AI and cloud migration have strained the energy infrastructure. As power consumption exceeds availability, the…
The demand for data centers driven by AI and cloud migration have strained the energy infrastructure. As power consumption exceeds availability, the…
Geteilt von Christian B. Fulda
-
I am happy to welcome back my colleague Veronica Dragalin, the former Chief Prosecutor of the Anti-Corruption Prosecution Office in the Republic of…
I am happy to welcome back my colleague Veronica Dragalin, the former Chief Prosecutor of the Anti-Corruption Prosecution Office in the Republic of…
Geteilt von Christian B. Fulda
-
Read a post on Jones Day's PTAB Litigation Blog discussing a decision by the Acting Director rescinding a previous discretionary denial after an…
Read a post on Jones Day's PTAB Litigation Blog discussing a decision by the Acting Director rescinding a previous discretionary denial after an…
Geteilt von Christian B. Fulda
Berufserfahrung
Ausbildung
-
Humboldt University of Berlin
-
–
Doctoral thesis under the auspices of Prof. Dr. Christian Tomuschat at the Institute for Public International Law and European Law of Humboldt University on democracy and international contracts.
-
-
–
German Elite Scholarship
-
-
–
-
–
Veröffentlichungen
-
Commercially Confidential Information at Risk: The European Medicines Agency Issues Disclosure Policy
Jones Day Client Alert
As if the fight for reasonable returns on investment into drug development, currently exemplified by the discussion on the pricing of innovative products, is not enough, the pharmaceutical industry is facing one of its biggest challenges in Europe: the protection of commercially confidential information ("CCI") contained in the marketing authorization dossier, the DNA of a product.
This Alert discusses the "Policy on Publication of Clinical Data for Medicinal Products for Human Use"…As if the fight for reasonable returns on investment into drug development, currently exemplified by the discussion on the pricing of innovative products, is not enough, the pharmaceutical industry is facing one of its biggest challenges in Europe: the protection of commercially confidential information ("CCI") contained in the marketing authorization dossier, the DNA of a product.
This Alert discusses the "Policy on Publication of Clinical Data for Medicinal Products for Human Use" adopted by the European Medicines Agency ("EMA") on October 2, 2014. It also summarizes the action points that industry should take to safeguard its investments in drug development.
Projekte
-
Dec 4, 2014: JD Webinar on EMA Disclosure of Marketing Authorization Data
The European Medicines Agency (EMA) has adopted a new policy on the publication of clinical data, effective for all marketing authorization applications filed as of January 1, 2015. Christian Fulda, of Jones Day's Intellectual Property Practice in Munich, will discuss how the policy requires a fundamental change in process regarding filings in Europe in order to protect commercially confidential data.
Sprachen
-
German
Muttersprache oder zweisprachig
-
English
Verhandlungssicher
-
French
Fließend
-
Italian
Gute Kenntnisse
-
Spanish
Gute Kenntnisse
Weitere Aktivitäten von Christian B. Fulda
-
On September 17, my colleagues Ted Chung, Jill Hengen, and Sidney Smith McClung will join David Glockner, Executive Vice President, Compliance…
On September 17, my colleagues Ted Chung, Jill Hengen, and Sidney Smith McClung will join David Glockner, Executive Vice President, Compliance…
Geteilt von Christian B. Fulda
-
I am happy to welcome my new colleague Jeffrey Ruskin to Jones Day. Jeff joins the Firm in New York as a partner in the Real Estate Practice. Read…
I am happy to welcome my new colleague Jeffrey Ruskin to Jones Day. Jeff joins the Firm in New York as a partner in the Real Estate Practice. Read…
Geteilt von Christian B. Fulda